Professional
Added to YB: 2025-08-08
Pitch date: 2025-06-30
LLY [bullish]
Eli Lilly and Company
+32.29%
current return
Author Info
No bio for this author
Company Info
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally.
Market Cap
$893.2B
Pitch Price
$776.68
Price Target
N/A
Dividend
0.60%
EV/EBITDA
31.99
P/E
48.80
EV/Sales
15.58
Sector
Pharmaceuticals
Category
growth
Baron Health Care Fund Added On Portfolio Holding: Eli Lilly and Company
LLY added to position: Leading GLP-1 pharma for diabetes/obesity. Mounjaro/Zepbound achieve 20%+ weight loss with CV benefits. Market could reach $150B. Oral orforglipron Phase 3 rivals Ozempic; obesity data this summer. Pipeline includes retatrutide, eloralintide, bimagrumab. Early innings—expect 3x revenue by 2030.
Read full article (1 min)